Bench-to-bedside translation of antibody drug conjugates (ADCs) using a multiscale mechanistic PK/PD model

This presentation will highlight the importance of understanding and quantitatively integrating the preclinical PK of antibody-drug conjugates (ADCs) to enable their preclinical-to-clinical translation. Two different case studies will be presented using the two clinically approved ADCs, trastuzumab emtansine (T-DM1) and brentuximab vedotin (SGN-35). Importance of understanding the tumor disposition of ADCs to enable the prediction of their clinical efficacy will be highlighted using SGN-35. In addition, the importance of understanding the whole body disposition of ADCs to enable the prediction of their clinical PK (and hence the toxicity) will be highlighted using T-DM1.